|
Real-time Estimate
Tradegate
03:00:52 2026-10-08 EDT
|
5-day change | 1st Jan Change | ||
| 15.57 EUR | +0.82% |
|
-3.03% | +45.37% |
| 10-05 | UBS Adjusts Price Target on Viatris to $26 From $23, Keeps Buy Rating | MT |
| 10-05 | Harrow Completes Acquisition of Tyrvaya Nasal Spray From Viatris | MT |
"Total Return" performance includes dividend payments over the period, as if they were reinvested at 100%.
The annotated values (TR) are displayed with their "Total Return" performance (only if available).
End-of-day quotes
The annotated values (TR) are displayed with their "Total Return" performance (only if available).
End-of-day quotes
Compared values
| Sector | Change | 5-day change | YTD change | 1-year change | 5-year change | Capi. | ST | MT | LT | ||
|---|---|---|---|---|---|---|---|---|---|---|---|
| VIATRIS INC. | Other Pharmaceuticals | -1.43% | -3.03% | +45.37% | +78.15% | +30.26% | 20.09B |
-
|
-
|
-
|
- Stock Market
- Stocks
- VTRS Stock
- 1VTRS Stock
- Charts Viatris Inc.
- Comparison Chart
Select your edition
All financial news and data tailored to specific country editions
